Skip to main content
. 2021 Aug 17;5(16):3102–3112. doi: 10.1182/bloodadvances.2021004373

Figure 3.

Figure 3.

Loss of BM erythroblasts in patients with AML. (A) Flow cytometry analysis of human BM erythroid precursors and of different erythropoiesis stages (I-IV). n = 4 control and 6 patients with AML . (B) Representative automatic population separator diagrams showing multiparametric analysis of flow cytometry data of human erythropoiesis in control and AML patients, based on the markers shown in supplemental Figure 2. (C) Comparison of plasma human erythroferrone (hERFE) in patients with AML at diagnosis (n = 10) and “control” patients (n = 12) with other conditions, mostly lymphoproliferative disorders (supplemental Table 3).